During 2024, 15.62% of trial completions were Phase III studies. In 2024, there were 7,089 completions, more than the 6,234 ...

Phase II trials are conducted to provide evidence ... suggesting that MultiCruzi could serve as an endpoint in future clinical trials.

Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...

Drugs are man-made miracles. They enhance our health, cure diseases, and extend our lives. However, drug development is not easy. It is a remarkably long, expensive, and complex process.

Researchers have applied AI to every step of the drug development process. But this might not be enough to design safe and effective drugs.

Lava Therapeutics has jettisoned its only wholly owned clinical-stage asset after the ... dubbed LAVA-1207, in a phase 1 trial for prostate-specific membrane antigen-positive metastatic castration ...